
Ethan Russo, MD on Emerging Research and Therapeutic Potential of CBG: A Webinar from CReDO Science
This presentation provided a comprehensive overview of cannabigerol (CBG), highlighting two studies on its effects on anxiety, stress, and pain.
On August 7th, 2024, Ethan Russo, neurologist, medical researcher, and founder of CReDO Science, presented a deep dive into research of cannabigerol (CBG), which Dr. Russo considered “the biggest up and coming cannabinoid” and stated that its use is becoming more prevalent, especially in the Western US. The hour-long webinar was presented by CReDO Science, sponsored by MM411 and GCNC, and a link to the recording will be temporarily available for registrants.
To begin the webinar, Dr. Russo discussed the first isolation of CBG in 1964 by Professors
The first research article on CBG, “
The second study, “
The presentation ended with comparisons between CBG and THC and between CBG and CBD, plus some of Dr. Russo’s projections on the economic prospects of CBG.
CReDO Science co-founder and chief operation officer Nishi Whiteley moderated the Q&A session at the end of the webinar, which covered over a dozen questions submitted by participants. Topics included the dosages that were recommended for participants, CBG’s effect on memory, full spectrum versus pure CBG, the effects of inhaled versus oral consumption, drug interactions, and more.
Related to this article








